1. The use of Lactobacillus rhamnosus LC705 alone or together with Lactobacillus rhamnosus GG to obtain a composition having an antiviral effect in a subject. The use according to claim 1, in which the composition is a pharmaceutical, food or feed product. The use of claim 2, wherein the composition is a pharmaceutical composition. The use according to any one of claims 1 to 3, in which the composition is intended for the treatment and / or prophylaxis of a respiratory infection in a subject. The use according to claim 1, in which the composition is intended to increase resistance to viruses that cause respiratory infections in a subject. The use of claim 1, wherein the composition enhances the expression of antiviral proteins. The use according to claim 1, in which the composition is intended to increase the level of antiviral cytokine (c) in a subject who may become infected or is infected by a respiratory infection. The use of claim 7, wherein the antiviral cytokine is selected from the group consisting of IFN-α, IFN-β, IL-1β, TNF-α and IP-10.9. The use of claim 4, wherein the respiratory infection is caused by a virus that is selected from the group consisting of the common cold virus (influenza), rhinovirus, adenovirus, parainfluenza virus, respiratory syncytial virus, enterovirus, coronavirus and Epstein-Barr virus. The use of claim 9, wherein the respiratory infection is an infection caused by an influenza virus. The use of or claim 10, wherein the influenza virus is selected from the group consisting of influenza A virus and influenza B.12 virus. The use according to claim 9, in which the composition is intended to prevent the proliferation of influenza virus and / or to reduce, slow down or inhibit the replication of the virus1. Применение Lactobacillus rhamnosus LC705 одного или вместе с Lactobacillus rhamnosus GG для получения композиции, обладающей противовирусным действием у субъекта.2. Применение по п.1, в котором композиция представляет фармацевтическ
